Edition:
United Kingdom

Ritter Pharmaceuticals Inc (RTTR.OQ)

RTTR.OQ on NASDAQ Stock Exchange Capital Market

0.82USD
24 May 2019
Change (% chg)

$0.00 (+0.35%)
Prev Close
$0.82
Open
$0.85
Day's High
$0.85
Day's Low
$0.82
Volume
7,933
Avg. Vol
99,790
52-wk High
$3.99
52-wk Low
$0.47

Latest Key Developments (Source: Significant Developments)

Ritter Pharmaceuticals Quarterly Loss Per Share $0.58
Wednesday, 15 May 2019 

May 14 (Reuters) - Ritter Pharmaceuticals Inc ::RITTER PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2019.QUARTERLY LOSS PER SHARE $0.58.  Full Article

Ritter Pharma Completes Dosing Of Last Patient In Pivotal 557-Subject Phase 3 Clinical Trial Of RP-G28 In Patients With Lactose Intolerance
Tuesday, 7 May 2019 

May 7 (Reuters) - Ritter Pharmaceuticals Inc ::RITTER PHARMACEUTICALS COMPLETES DOSING OF LAST PATIENT IN PIVOTAL 557-SUBJECT PHASE 3 CLINICAL TRIAL OF RP-G28 IN PATIENTS WITH LACTOSE INTOLERANCE.RITTER PHARMACEUTICALS INC - NO SAFETY SIGNALS HAVE BEEN REPORTED TO DATE WHICH CONTINUES TO SUPPORT WELL-TOLERATED SAFETY AND TOLERABILITY PROFILE.RITTER PHARMACEUTICALS INC - REMAIN ON TRACK FOR DATA READOUT IN EARLY Q4 2019 FOR LIBERATUS TRIAL.  Full Article

Ritter Pharmaceuticals Completes Enrollment In Pivotal Phase 3 Clinical Trial Of Rp-G28
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Ritter Pharmaceuticals Inc ::RITTER PHARMACEUTICALS COMPLETES ENROLLMENT IN PIVOTAL PHASE 3 CLINICAL TRIAL OF RP-G28 IN PATIENTS WITH LACTOSE INTOLERANCE.RITTER PHARMACEUTICALS INC - TOP-LINE DATA READOUT EXPECTED IN EARLY Q4 2019.RITTER PHARMACEUTICALS INC - NO SAFETY SIGNALS HAVE BEEN REPORTED TO DATE WHICH CONTINUES TO CONFIRM WELL-TOLERATED SAFETY AND TOLERABILITY PROFILE.  Full Article

Ritter Pharmaceuticals - On Dec 26, Got Notice From Nasdaq Notifying Co No Longer Complies With Minimum Bid Price Requirement For Continued Listing
Friday, 28 Dec 2018 

Dec 28 (Reuters) - Ritter Pharmaceuticals Inc ::RITTER PHARMACEUTICALS - ON DEC 26, GOT NOTICE FROM NASDAQ NOTIFYING CO NO LONGER COMPLIES WITH MINIMUM BID PRICE REQUIREMENT FOR CONTINUED LISTING.  Full Article

Ritter Pharmaceuticals Q3 Loss Per Share $0.86
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Ritter Pharmaceuticals Inc ::RITTER PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2018 AND RECENT PROGRESS.Q3 LOSS PER SHARE $0.86.Q3 EARNINGS PER SHARE VIEW $-0.78 -- THOMSON REUTERS I/B/E/S.  Full Article

Ritter Pharmaceuticals Announces 1-For-10 Reverse Stock Split
Thursday, 22 Mar 2018 

March 22 (Reuters) - Ritter Pharmaceuticals Inc ::RITTER PHARMACEUTICALS ANNOUNCES 1-FOR-10 REVERSE STOCK SPLIT.RITTER PHARMACEUTICALS INC - ‍ANNOUNCED A 1-FOR-10 REVERSE SPLIT OF ITS COMMON STOCK, PAR VALUE $0.001 PER SHARE EFFECTIVE MARCH 23, 2018​.  Full Article

Ritter Pharmaceuticals Reports Q4 Loss Per Share $0.11
Monday, 19 Mar 2018 

March 19 (Reuters) - Ritter Pharmaceuticals Inc ::RITTER PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $0.11.‍ ON TRACK TO START SCREENING IN Q2​ FOR FIRST PIVOTAL PHASE 3 CLINICAL TRIAL OF RP-G28 IN LACTOSE INTOLERANCE.‍ AS OF DECEMBER 31, 2017, HAD CASH AND CASH EQUIVALENTS OF APPROXIMATELY $22.6 MILLION​.  Full Article

Ritter Pharmaceuticals Reports Microbiome Data From Phase 2B Study Of RP-G28 Promotes Beneficial Adaptation Of The Gut Microbiome
Monday, 12 Mar 2018 

March 12 (Reuters) - Ritter Pharmaceuticals Inc ::RITTER PHARMACEUTICALS REPORTS MICROBIOME DATA FROM PHASE 2B STUDY OF RP-G28 PROMOTES BENEFICIAL ADAPTATION OF THE GUT MICROBIOME.RITTER PHARMACEUTICALS INC - ‍DURING PHASE 2A STUDY, OBSERVED AN INCREASE IN BIFIDOBACTERIA, WHICH WERE CONFIRMED IN LARGER PHASE 2B STUDY​.RITTER PHARMACEUTICALS INC - ‍PHASE 3 CLINICAL TRIAL OF RP-G28 FOR TREATMENT OF LACTOSE INTOLERANCE IN Q2 2018​.  Full Article

‍sabby Management reports 9.94 pct passive stakee in Ritter Pharmaceuticals
Tuesday, 3 Oct 2017 

Oct 3 (Reuters) - Ritter Pharmaceuticals Inc :‍sabby Management, LLC​ reports 9.94 percent passive stakee in Ritter Pharmaceuticals Inc as of September 29 - sec filing.  Full Article

RITTER PHARMA RAISES $23 MLN TO FUND PHASE 3 CLINICAL PROGRAM IN LACTOSE INTOLERANCE
Tuesday, 3 Oct 2017 

Oct 3 (Reuters) - Ritter Pharmaceuticals Inc ::RITTER PHARMACEUTICALS, INC. RAISES $23 MILLION TO FUND INITIATION OF ITS PHASE 3 CLINICAL PROGRAM IN LACTOSE INTOLERANCE.PROCEEDS WILL ALLOW CO TO FUND INITIATION OF ITS PHASE 3 CLINICAL PROGRAM OF RP-G28 FOR TREATMENT OF LACTOSE INTOLERANCE.‍PHASE 3 CLINICAL PROGRAM OF RP-G28 FOR TREATMENT OF LACTOSE INTOLERANCE EXPECTED TO BEGIN IN FIRST HALF OF 2018​.  Full Article